MicroRNA Biomarkers in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) remains a major global health challenge, with high incidence and poor prognosis owing to late diagnosis and limited curative options. In recent years, microRNAs (miRNAs) have emerged as promising non-invasive biomarkers for early detection, prognostic stratification and monitoring of therapeutic response. These short, non-coding RNAs regulate key oncogenic and tumour-suppressive pathways, and their differential expression in blood, serum or plasma can reflect tumour burden and liver injury. Advantages of circulating miRNAs include remarkable stability, ease of quantification and potential for panel-based assays. Integration with existing markers such as alpha-fetoprotein (AFP) and application of machine learning for pattern recognition have further enhanced diagnostic accuracy. However, challenges remain in standardising sample processing, normalising data and validating findings across diverse patient populations. Continued efforts to harmonise protocols, define reference controls and explore exosomal versus free miRNA fractions are critical to translate miRNA biomarkers into routine clinical practice.

Research from Nature Portfolio

In a 2024 study investigating Egyptian patients with HCC, a machine learning framework was developed to evaluate circulating miRNAs as diagnostic and prognostic markers. Data preprocessing addressed heterogeneity across three independent cohorts, while a novel Binary African Vulture Optimisation algorithm selected key miRNA features. Support vector machine classification with cross-validation yielded sensitivities and specificities exceeding 95% in differentiating HCC from cirrhosis and healthy controls, highlighting miR-483-5p, miR-21 and miR-155 as particularly informative.

Foundational profiling efforts have employed whole-miRNome analysis to pinpoint deregulated miRNAs across multiple validation cohorts. Distinct signatures of upregulated miRNAs such as miR-122-5p and miR-125b-5p, together with sets of downregulated candidates, were shown to discriminate HCC from chronic hepatitis and cirrhosis. Associations between specific miRNA levels and overall survival further underscored their prognostic value, supporting their integration into risk stratification workflows.

MicroRNA Biomarkers in Hepatocellular Carcinoma publication trend

The graph below shows the total number of articles in microrna biomarkers in hepatocellular carcinoma across all publications each year (not limited to Nature Index journals).

Technical terms

MicroRNA (miRNA): Small non-coding RNA molecules (≈22 nucleotides) that regulate gene expression post-transcriptionally and can serve as disease indicators.

Hepatocellular carcinoma (HCC): The most common primary liver cancer, often arising in the context of chronic liver disease and cirrhosis.

Liquid biopsy: Non-invasive sampling of bodily fluids to detect circulating tumour-derived molecules, including miRNAs and cell-free nucleic acids.

Alpha-fetoprotein (AFP): A serum glycoprotein conventionally used as a biomarker for HCC, often combined with miRNA assays for improved accuracy.

Area under the curve (AUC): A metric derived from receiver operating characteristic analysis that quantifies the overall diagnostic performance of a biomarker.

References

1. Circulating miRNA’s biomarkers for early detection of hepatocellular carcinoma in Egyptian patients based on machine learning algorithms. Scientific Reports (2024).
2. Hepatocellular carcinoma associated microRNA expression signature: integrated bioinformatics analysis, experimental validation and clinical significance. Oncotarget (2015).
3. Diagnostic Significance of hsa-miR-21-5p, hsa-miR-192-5p, hsa-miR-155-5p, hsa-miR-199a-5p Panel and Ratios in Hepatocellular Carcinoma on Top of Liver Cirrhosis in HCV-Infected Patients. International Journal of Molecular Sciences (2023).
4. Circulating microRNAs as promising diagnostic biomarkers for hepatocellular carcinoma: a systematic review and meta-analysis. Frontiers in Molecular Biosciences (2024).
5. Emerging role of circulating cell-free RNA as a non-invasive biomarker for hepatocellular carcinoma. Critical Reviews in Oncology/Hematology (2024).